Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 and SKB118 in EGFR-mutant Advanced Non-squamous NSCLC
NCT07854509Phase 2Not yet recruiting
- Sponsor
- Kelun-Biotech
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and CR-001 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Kelun-Biotech. Primary endpoints: Safety and Tolerability at 24 months and Objective Response Rate at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanCR-001
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07854509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854509.